



PORTUGAL

Number of new cases

69 567

Number of deaths


33 762

Number of prevalent cases (5-year)

203 570


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	4 800 831	5 339 737	10 140 568
Incidence*			
Number of new cancer cases	37 865	31 702	69 567
Age-standardized incidence rate	342.7	258.5	294.6
Risk of developing cancer before the age of 75 years (cum. risk %)	33.5	24.3	28.6
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Lung	Breast Colorectum Lung	Colorectum Breast Prostate
Mortality*			
Number of cancer deaths	19 510	14 252	33 762
Age-standardized mortality rate	148.8	77.5	109.0
Risk of dying from cancer before the age of 75 years (cum. risk %)	15.1	7.7	11.2
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Prostate	Breast Colorectum Lung	Lung Colorectum Stomach
Prevalence*			
5-year prevalent cases	105 464	98 106	203 570



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	7 529	19.9%
2nd	Colorectum	6 092	16.1%
3rd	Lung	4 253	11.2%
4th	Bladder	2 660	7.0%
5th	Stomach	2 163	5.7%
-	Others	15 168	40.1%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	8 954	28.2%
2nd	Colorectum	4 483	14.1%
3rd	Lung	1 902	6.0%
4th	Thyroid	1 794	5.7%
5th	Stomach	1 505	4.7%
-	Others	13 064	41.2%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Colorectum	10 575	15.2%
2nd	Breast	8 954	12.9%
3rd	Prostate	7 529	10.8%
4th	Lung	6 155	8.8%
5th	Stomach	3 668	5.3%
-	Others	32 686	47.0%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Colorectum	10 575	1	15.2	4.5	4 809	2	14.2	1.4	31 861	314.2
Breast	8 954	2	12.9	9.2	2 211	4	6.5	1.5	36 117	676.4
Prostate	7 529	3	10.8	7.9	2 083	6	6.2	0.78	29 216	608.6
Lung	6 155	4	8.8	2.9	5 077	1	15.0	2.2	7 523	74.2
Stomach	3 668	5	5.3	1.5	2 578	3	7.6	0.87	4 821	47.5
Bladder	3 517	6	5.1	1.4	1 392	8	4.1	0.32	11 014	108.6
NHL	2 437	7	3.5	1.2	1 052	10	3.1	0.35	7 757	76.5
Thyroid	2 260	8	3.2	1.5	109	24	0.32	0.02	8 637	85.2
Pancreas	2 158	9	3.1	0.78	2 086	5	6.2	0.73	1 607	15.9
Liver	1 740	10	2.5	0.78	1 611	7	4.8	0.68	1 971	19.4
Kidney	1 624	11	2.3	0.84	594	14	1.8	0.19	5 059	49.9
Leukaemia	1 565	12	2.3	0.70	1 072	9	3.2	0.34	4 425	43.6
Corpus uteri	1 401	13	2.0	1.3	439	17	1.3	0.27	5 270	98.7
Lip, oral cavity	1 293	14	1.9	0.70	428	18	1.3	0.20	4 155	41.0
Melanoma	1 215	15	1.7	0.61	308	20	0.91	0.11	4 477	44.2
Brain CNS	1 203	16	1.7	0.61	1 048	11	3.1	0.48	4 553	44.9
Multiple myeloma	994	17	1.4	0.41	689	12	2.0	0.22	2 706	26.7
Cervix uteri	897	18	1.3	1.0	459	16	1.4	0.33	3 101	58.1
Larynx	726	19	1.0	0.43	375	19	1.1	0.19	2 566	25.3
Oesophagus	687	20	0.99	0.38	636	13	1.9	0.31	961	9.5
Ovary	682	21	0.98	0.64	472	15	1.4	0.37	1 929	36.1
Oropharynx	570	22	0.82	0.36	274	21	0.81	0.16	1 811	17.9
Hypopharynx	370	23	0.53	0.23	195	22	0.58	0.12	847	8.4
Hodgkin lymphoma	337	24	0.48	0.25	68	27	0.20	0.03	1 351	13.3
Testis	293	25	0.42	0.48	24	31	0.07	0.03	1 273	26.5
Vulva	196	26	0.28	0.08	94	25	0.28	0.02	523	9.8
Gallbladder	169	27	0.24	0.07	128	23	0.38	0.05	203	2.0
Salivary glands	128	28	0.18	0.07	66	29	0.20	0.02	434	4.3
Penis	117	29	0.17	0.11	32	30	0.10	0.02	371	7.7
Nasopharynx	107	30	0.15	0.07	67	28	0.20	0.04	370	3.7
Kaposi sarcoma	102	31	0.15	0.06	11	33	0.03	0.00	319	3.2
Mesothelioma	79	32	0.11	0.03	73	26	0.22	0.03	88	0.87
All cancers	69 567	-	-	28.6	33 762	-	-	11.2	203 570	-
All cancers excl. NMSC	66 600	-	-	28.0	33 503	-	-	11.1	193 671	-

Data source and methods

Incidence



Country-specific data source: Sub-national registries
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from country-specific cancer registry data

Mortality

Country-specific data source: National (WHO) and Eurostat
 Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

